VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE